Patients infected with COVID-19 are at higher risk of thrombosis, suggesting an important role of COVID-19 induced coagulopathy. Abnormal coagulation parameters such as elevation in D-dimer are found in patients, with frequent thrombotic events ranging from peripheral ischemia, pulmonary thromboembolism to disseminated intravascular coagulation. Recently, the role of antiphospholipid antibodies (aPL) in the pathophysiology of COVID-19 have been questioned but it remains unclear whether they

more »

... ribute to coagulopathy. We aim to evaluate the presence of aPL, including LAC, aCL (IgG, IgM), aβ2GPI (IgG, IgM) in a cohort of patients with SARS-CoV-2, study clinical associations and discuss the relevance. The relevance of aPLs in patients with COVID-19 is yet to be determined. Inflammation is closely associated to thrombosis and the presence of inflammatory mediators in COVID-19 infection can lead to thrombosis. Further studies are needed before to determine the role of aPL in COVID-19 patients and their relationship with thrombosis. The presence of aPL should be carefully interpreted as it is important to evaluate the persistence of aPL positivity in patients infected with COVID-19.